GOSS News and Press, Gossamer Bio Inc. From 10/22/19

Shares of Gossamer Bio (NASDAQ: GOSS) fell as much as 14.6% at the market open on Tuesday, then soared as much as 21.4% less than an hour later. The biotech stock was up by 6.7% as of 11:20 a.m. EDT. Why such wild swings?  Novartis (NYSE: NVS) announced that its experimental asthma ...

Tile Shop Holdings (NASDAQ: TTS )  -69%  on voluntarily  delisting  common stock from the Nasdaq. More news on: Tile Shop Holdings, Inc., The Howard Hughes Corporation, Top Ships Inc., Stocks on the move, Read more ...

Seven biotech companies with initial valuations north of $1 billion began trading during the first nine months of 2019. Overall, these companies performed well. Their average and median returns were 13% and 14% respectively. In comparison, the SPDR S&P 500 ETF (NYSEARCA: SPY) and the Fide...

Insider buying declined significantly last week with insiders purchasing $57.61 million of stock last week compared to $252.96 million in the week prior. Selling also declined with insiders selling $683.67 million of stock last week compared to $1.20 billion in the week prior. With the end...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced Otello Stampacchia, Ph.D., of Omega Funds, resigned fro...

This article is part of a series that provide an ongoing analysis of the changes made to Baupost Group's 13F stock portfolio on a quarterly basis. It is based on Klarman's regulatory 13F Form filed on 08/13/2019. Please visit our Tracking Seth Klarman's Baupost Group Holdings article for a...

Gossamer Bio, Inc. (GOSS) Q2 2019 Earnings Conference Call August 08, 2019, 16:30 ET Company Participants Bryan Giraudo - CFO Sheila Gujrathi - Co-Founder, President, CEO & Director Jakob Dupont - Chief Medical Officer Conference Call Participants Joseph Schwartz - SVB ...

The following slide deck was published by Gossamer Bio, Inc. in conjunction with this Read more ...